Explore
Validate
Learn14-9908-80
antibody from Invitrogen Antibodies
Targeting: TNFRSF10B
CD262, DR5, KILLER, TRAIL-R2, TRAILR2, TRICK2A, TRICKB
Immunocytochemistry
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [7]
- Comments [0]
- Validations
- Immunohistochemistry [1]
- Flow cytometry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 14-9908-80 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Anti-CD262 (DR5) Monoclonal Antibody (DJR2-4 (7-8)), eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: The DJR2-4 monoclonal antibody reacts with human DR5, also known as TRAIL-R2, Apo2, TRICK2 and KILLER. DR5 binds to TRAIL, activates NF-kappaB, and induces TRAIL-mediated apoptosis. DR5 is expressed broadly by normal tissues as well as several tumor cells. Applications Reported: The DJR2-4 (a.k.a. 7-8) antibody has been reported for use in flow cytometric analysis. Applications Tested: The DJR2-4 (a.k.a. 7-8) antibody has been tested by flow cytometric analysis of human MOLT-4 cell line and human DR5-transfected cells. This can be used at less than or equal to 1 µg per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Purity: Greater than 90%, as determined by SDS-PAGE. Aggregation: Less than 10%, as determined by HPLC. Filtration: 0.2 µm post-manufacturing filtered.
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- DJR2-4 (7-8)
- Vial size
- 25 µg
- Concentration
- 0.5 mg/mL
- Storage
- 4° C
Submitted references Targeting the metabolic pathway of human colon cancer overcomes resistance to TRAIL-induced apoptosis.
Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models.
TRAIL-mediated apoptosis in breast cancer cells cultured as 3D spheroids.
MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells.
Lack of a functional VHL gene product sensitizes renal cell carcinoma cells to the apoptotic effects of the protein synthesis inhibitor verrucarin A.
A whole-genome RNAi screen identifies an 8q22 gene cluster that inhibits death receptor-mediated apoptosis.
Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells.
Carr RM, Qiao G, Qin J, Jayaraman S, Prabhakar BS, Maker AV
Cell death discovery 2016;2:16067
Cell death discovery 2016;2:16067
Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models.
Liu Y, Hawkins OE, Vilgelm AE, Pawlikowski JS, Ecsedy JA, Sosman JA, Kelley MC, Richmond A
Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Dec 1;21(23):5338-48
Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Dec 1;21(23):5338-48
TRAIL-mediated apoptosis in breast cancer cells cultured as 3D spheroids.
Chandrasekaran S, Marshall JR, Messing JA, Hsu JW, King MR
PloS one 2014;9(10):e111487
PloS one 2014;9(10):e111487
MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells.
Turner A, Li LC, Pilli T, Qian L, Wiley EL, Setty S, Christov K, Ganesh L, Maker AV, Li P, Kanteti P, Das Gupta TK, Prabhakar BS
PloS one 2013;8(2):e56817
PloS one 2013;8(2):e56817
Lack of a functional VHL gene product sensitizes renal cell carcinoma cells to the apoptotic effects of the protein synthesis inhibitor verrucarin A.
Woldemichael GM, Turbyville TJ, Vasselli JR, Linehan WM, McMahon JB
Neoplasia (New York, N.Y.) 2012 Aug;14(8):771-7
Neoplasia (New York, N.Y.) 2012 Aug;14(8):771-7
A whole-genome RNAi screen identifies an 8q22 gene cluster that inhibits death receptor-mediated apoptosis.
Dompe N, Rivers CS, Li L, Cordes S, Schwickart M, Punnoose EA, Amler L, Seshagiri S, Tang J, Modrusan Z, Davis DP
Proceedings of the National Academy of Sciences of the United States of America 2011 Oct 25;108(43):E943-51
Proceedings of the National Academy of Sciences of the United States of America 2011 Oct 25;108(43):E943-51
Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells.
Earel JK Jr, VanOosten RL, Griffith TS
Cancer research 2006 Jan 1;66(1):499-507
Cancer research 2006 Jan 1;66(1):499-507
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Knockdown of CD262 (DR5) was achieved by transfecting MDA-MB-231 cells with CD262 (DR5) specific siRNA (Silencer® select Product # s16756). Immunofluorescence analysis was performed using untransfected MDA-MB-231 cells (panels a, d), transfected with non-specific scrambled siRNA (panels b,e) and transfected with CD262 (DR5) specific siRNAs (panel c,f). Cells were fixed, permeabilized, and probed with CD262 (DR5) Monoclonal Antibody (DJR2-4 (7-8)), eBioscience™(Product # 14-9908-82, 5µg/ml), followed by labelling with Goat anti-Mouse IgG (H+L) Superclonal™ Secondary Antibody, Alexa Fluor 488 (Product # A28175, 1:2000). Nuclei (blue) were stained using ProLong™ Diamond Antifade Mountant with DAPI (Product # P36962) and Rhodamine Phalloidin (Product # R415, 1:300) was used for cytoskeletal F-actin (red) staining. Reduction of specific cytoplasmic localization was observed upon siRNA mediated knockdown (panel c,f) confirming specificity of the antibody to CD262 (DR5). The images were captured at 60X magnification.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Staining of human DR5-transfected cells with 0.5 µg of Mouse IgG1 K Isotype Control Purified (Product # 14-4714-82) (open histogram) or 0.5 µg of Anti-Human CD262 (DR5) Purified (filled histogram) followed by Anti-Mouse IgG Biotin (Product # 13-4013-85) and Streptavidin PE (Product # 12-4317-87). Total viable cells were used for analysis.
